In Brief: Abbott Outlook; CFSAN’s Landa To Retire; FTC Claim Substantiation
This article was originally published in The Tan Sheet
Executive Summary
Abbott “on track” in China recovery; CFSAN seeks new director; FTC adds new substantiation elements to settlement; NAD advises iSatori to amend claims energy supplement claims; FDA wants proof deficiencies are corrected; and FDA warns about chelation supplement.
You may also be interested in...
Complaint Reminds CVS: No Support For Memory Claim In Fish Oil Study
A complaint filed by CSPI working with law firms in New York and Washington extends the dispute over cognitive claims for vitamin and supplement products from enforcement by FTC and FDA and questions from Congress to consumers' class action complaints.
Epidemiologist, “Coalition Builder” Mayne To Lead CFSAN
Susan Mayne will succeed Michael Landa at the CFSAN helm in January 2015. Supplement industry stakeholders are encouraged FDA filled the post ahead of Landa’s retirement after feeling the impact of vacancies in CFSAN offices regulating the industry.
Epidemiologist, “Coalition Builder” Mayne To Lead CFSAN
Susan Mayne will succeed Michael Landa at the CFSAN helm in January 2015. Supplement industry stakeholders are encouraged FDA filled the post ahead of Landa’s retirement after feeling the impact of vacancies in CFSAN offices regulating the industry.